BH3:FRA
PTC Therapeutics, Inc.
55,00 €
arrow_downward
-0,61%(-0,34) 1D
9 қаз., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
55,00 €
High
55,00 €
Low
55,00 €
Mkt. cap
5,40 млрд
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
Open
55,00 €
High
55,00 €
Low
55,00 €
Mkt. cap
5,40 млрд
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
News stories
From web sources and news partners
Investing.com Nigeria
·
37 минут бұрын
Form 144 PTC THERAPEUTICS For: 10 October By Investing.com
MarketBeat
·
18 сағат бұрын
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages
Investing.com UK
·
1 күн бұрын
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded1998 ж. 01 қаң.
HeadquartersУаррэн Тауншип, Нью-Джерси, Америка Құрама Штаттары
Sector-
Websiteptcbio.com